Aspen Pharmacare reported on Thursday a 26% increase in normalised headline earnings per share to R8.72 in the six months to December.
Revenue climbed by 11% to R21.9 billion in the review period while net profit rose 30% to R3.7 billion.
Aspen makes about 80% of its sales outside of South Africa, which could negatively impact future results if the rand remains strong.
Aspen Pharmacare is Africa’s largest maker of generic drugs.
The Money Show’s Bruce Whitfield interviewed Aspen Pharmacare CEO Stephen Saad.
Saad discussed his company’s results, and reflected on how it responded to rumours of investigations by short-seller Viceroy.
Listen to the interview in the audio below (and/or scroll down for quotes from it).
We never felt vulnerable. We never had off-balance sheet debt…— Stephen Saad, Aspen Pharmacare
It’s not your income that matters; it’s your bank account!— Stephen Saad, Aspen Pharmacare
We’re happy to use debt, because we’re happy with our cash-flows…— Stephen Saad, Aspen Pharmacare
Our profits are matched by cash…— Stephen Saad, Aspen Pharmacare
We changed strategy… We’ve learned lessons… We’ve changed tactics… It was a massive switch for us the last four years…— Stephen Saad, Aspen Pharmacare
We may be South Africa’s most global company…— Stephen Saad, Aspen Pharmacare
We haven’t issued a share since 2009.— Stephen Saad, Aspen Pharmacare
We don’t expand for the sake of expanding…— Stephen Saad, Aspen Pharmacare
Enter your email address in the form below to receive a newsletter containing the most-read articles of the week from Bruce Whitfield’s The Money Show every Friday morning in your inbox.
Recommendedby NEWSROOM AI
Bruce Whitfield interviews John Oliphant, former Principal Executive Officer at the Government Employees Pension Fund.
Taxpayer? You may want to check this out. Bruce Whitfield interviews Pieter du Toit, Assistant Editor of In-depth News at News24.
A look at how our desire for spice changed the world and how it continues to do so.
The Money Show’s Bruce Whitfield interviews Rui Morais, CFO at Dis-Chem Pharmacies.
Testimonies at the Sars Inquiry has many South African taxpayers panicked. Bruce Whitfield interviews Sars' Mark Kingon.
The aim is to take profits away from criminals and to regulate a product that millions of Canadians consume illegally anyway.
Deputy Editor at Financial Mail, Sikhonathi Mantshantsha, seems to be finding excuses as to why its leaders are in trouble.
The Money Show’s Bruce Whitfield interviews Madzonga, who claims innocence and that Chairperson Tshifhiwa Matodzi lied to him.
Here we go again… The Money Show’s Bruce Whitfield interviews Africa Connected Host Lee Kasumba.
Some of the women who used these tests shared their heartbreaking stories with Business Insider Online.
Marc Sevitz of Tax Tim says it is scary to think the system might collapse and taxpayers will have to file manually.
Khabazela shares some of the most popular tweets, posts, and videos on 'What's gone viral'.
News 24 investigative journalist Kyle Cowan reports that Zuma was granted the loan despite the fact that he could not afford it.
Claims have been made that the perfume industry don't want consumers to know the real cost of making these products.